Open AccessTreating fatty liver disease by modulating mitochondrial pyruvate metabolism
Author(s) -
Colca Jerry R.,
McDonald William G.,
McCommis Kyle S.,
Finck Brian N.
Publication year - 2017
Publication title -
hepatology communications
Language(s) - English
Resource type - Journals
ISSN - 2471-254X
DOI - 10.1002/hep4.1036
Subject(s) - hepatology , nonalcoholic steatohepatitis , steatohepatitis , nonalcoholic fatty liver disease , mitochondrion , fatty liver , medicine , fibrosis , pathophysiology , disease , endocrinology , pharmacology , bioinformatics , biology , biochemistry
Modifying the entry of pyruvate into mitochondria may provide a unique approach to treat metabolic disease. The pharmacology of a new class of insulin sensitizers directed against a newly identified mitochondrial target may treat many aspects of nonalcoholic steatohepatitis, including fibrosis. This commentary suggests treating nonalcoholic steatohepatitis through a newly identified mechanism consistent with pathophysiology. ( Hepatology Communications 2017;1:193‐197)